The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient
<b>Background:</b> Mutations in bone morphogenetic protein receptor type II (BMPR2) are leading to the development of hereditary pulmonary arterial hypertension (PAH). In non-hereditary forms of PAH, perturbations in the transforming growth factor-β (TGF-β)/BMP-axis are believed to cause...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/6/1422 |
| _version_ | 1797565831665680384 |
|---|---|
| author | Chris Happé Kondababu Kurakula Xiao-Qing Sun Denielli da Silva Goncalves Bos Nina Rol Christophe Guignabert Ly Tu Ingrid Schalij Karien C. Wiesmeijer Olga Tura-Ceide Anton Vonk Noordegraaf Frances S. de Man Harm Jan Bogaard Marie-José Goumans |
| author_facet | Chris Happé Kondababu Kurakula Xiao-Qing Sun Denielli da Silva Goncalves Bos Nina Rol Christophe Guignabert Ly Tu Ingrid Schalij Karien C. Wiesmeijer Olga Tura-Ceide Anton Vonk Noordegraaf Frances S. de Man Harm Jan Bogaard Marie-José Goumans |
| author_sort | Chris Happé |
| collection | DOAJ |
| description | <b>Background:</b> Mutations in bone morphogenetic protein receptor type II (BMPR2) are leading to the development of hereditary pulmonary arterial hypertension (PAH). In non-hereditary forms of PAH, perturbations in the transforming growth factor-β (TGF-β)/BMP-axis are believed to cause deficient BMPR2 signaling by changes in receptor expression, the activity of the receptor and/or downstream signaling. To date, BMPR2 expression and its activity in the lungs of patients with non-hereditary PAH is poorly characterized. In recent decades, different animal models have been used to understand the role of BMPR2 signaling in PAH pathophysiology. Specifically, the monocrotaline (MCT) and Sugen–Hypoxia (SuHx) models are extensively used in interventional studies to examine if restoring BMPR2 signaling results in PAH disease reversal. While PAH is assumed to develop in patients over months or years, pulmonary hypertension in experimental animal models develops in days or weeks. It is therefore likely that modifications in BMP and TGF-β signaling in these models do not fully recapitulate those in patients. In order to determine the translational potential of the MCT and SuHx models, we analyzed the BMPR2 expression and activity in the lungs of rats with experimentally induced PAH and compared this to the BMPR2 expression and activity in the lungs of PAH patients. <b>Methods:</b> the BMPR2 expression was analyzed by Western blot analysis and immunofluorescence (IF) microscopy to determine the quantity and localization of the receptor in the lung tissue from normal control subjects and patients with hereditary or idiopathic PAH, as well as in the lungs of control rats and rats with MCT or SuHx-induced PAH. The activation of the BMP pathway was analyzed by determining the level and localization of phosphorylated Smad1/5/8 (pSmad 1/5/8), a downstream mediator of canonical BMPR2 signaling. <b>Results:</b> While BMPR2 and pSmad 1/5/8 expression levels were unaltered in whole lung lysates/homogenates from patients with hereditary and idiopathic PAH, IF analysis showed that BMPR2 and pSmad 1/5/8 levels were markedly decreased in the pulmonary vessels of both PAH patient groups. Whole lung BMPR2 expression was variable in the two PAH rat models, while in both experimental models the expression of BMPR2 in the lung vasculature was increased. However, in the human PAH lungs, the expression of pSmad 1/5/8 was downregulated in the lung vasculature of both experimental models. <b>Conclusion:</b> BMPR2 receptor expression and downstream signaling is reduced in the lung vasculature of patients with idiopathic and hereditary PAH, which cannot be appreciated when using human whole lung lysates. Despite increased BMPR2 expression in the lung vasculature, the MCT and SuHx rat models did develop PAH and impaired downstream BMPR2-Smad signaling similar to our findings in the human lung. |
| first_indexed | 2024-03-10T19:18:31Z |
| format | Article |
| id | doaj.art-0258be1fdecb410e89fae97cee3ce1ca |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T19:18:31Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-0258be1fdecb410e89fae97cee3ce1ca2023-11-20T03:10:23ZengMDPI AGCells2073-44092020-06-0196142210.3390/cells9061422The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the PatientChris Happé0Kondababu Kurakula1Xiao-Qing Sun2Denielli da Silva Goncalves Bos3Nina Rol4Christophe Guignabert5Ly Tu6Ingrid Schalij7Karien C. Wiesmeijer8Olga Tura-Ceide9Anton Vonk Noordegraaf10Frances S. de Man11Harm Jan Bogaard12Marie-José Goumans13Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsLaboratory for Cardiovascular Cell Biology, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsINSERM UMR_S 999, Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, FranceINSERM UMR_S 999, Hôpital Marie Lannelongue, 92350 Le Plessis-Robinson, FranceAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsLaboratory for Cardiovascular Cell Biology, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The NetherlandsDepartment of Pulmonary Medicine, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, 08036 Barcelona, SpainAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Pulmonology, Amsterdam Cardiovascular Sciences, 1081 HV Amsterdam, The NetherlandsLaboratory for Cardiovascular Cell Biology, Department of Cell and Chemical Biology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands<b>Background:</b> Mutations in bone morphogenetic protein receptor type II (BMPR2) are leading to the development of hereditary pulmonary arterial hypertension (PAH). In non-hereditary forms of PAH, perturbations in the transforming growth factor-β (TGF-β)/BMP-axis are believed to cause deficient BMPR2 signaling by changes in receptor expression, the activity of the receptor and/or downstream signaling. To date, BMPR2 expression and its activity in the lungs of patients with non-hereditary PAH is poorly characterized. In recent decades, different animal models have been used to understand the role of BMPR2 signaling in PAH pathophysiology. Specifically, the monocrotaline (MCT) and Sugen–Hypoxia (SuHx) models are extensively used in interventional studies to examine if restoring BMPR2 signaling results in PAH disease reversal. While PAH is assumed to develop in patients over months or years, pulmonary hypertension in experimental animal models develops in days or weeks. It is therefore likely that modifications in BMP and TGF-β signaling in these models do not fully recapitulate those in patients. In order to determine the translational potential of the MCT and SuHx models, we analyzed the BMPR2 expression and activity in the lungs of rats with experimentally induced PAH and compared this to the BMPR2 expression and activity in the lungs of PAH patients. <b>Methods:</b> the BMPR2 expression was analyzed by Western blot analysis and immunofluorescence (IF) microscopy to determine the quantity and localization of the receptor in the lung tissue from normal control subjects and patients with hereditary or idiopathic PAH, as well as in the lungs of control rats and rats with MCT or SuHx-induced PAH. The activation of the BMP pathway was analyzed by determining the level and localization of phosphorylated Smad1/5/8 (pSmad 1/5/8), a downstream mediator of canonical BMPR2 signaling. <b>Results:</b> While BMPR2 and pSmad 1/5/8 expression levels were unaltered in whole lung lysates/homogenates from patients with hereditary and idiopathic PAH, IF analysis showed that BMPR2 and pSmad 1/5/8 levels were markedly decreased in the pulmonary vessels of both PAH patient groups. Whole lung BMPR2 expression was variable in the two PAH rat models, while in both experimental models the expression of BMPR2 in the lung vasculature was increased. However, in the human PAH lungs, the expression of pSmad 1/5/8 was downregulated in the lung vasculature of both experimental models. <b>Conclusion:</b> BMPR2 receptor expression and downstream signaling is reduced in the lung vasculature of patients with idiopathic and hereditary PAH, which cannot be appreciated when using human whole lung lysates. Despite increased BMPR2 expression in the lung vasculature, the MCT and SuHx rat models did develop PAH and impaired downstream BMPR2-Smad signaling similar to our findings in the human lung.https://www.mdpi.com/2073-4409/9/6/1422pulmonary arterial hypertensionBMPR2BMP and TGF-β signalinganimal models of pulmonary hypertension |
| spellingShingle | Chris Happé Kondababu Kurakula Xiao-Qing Sun Denielli da Silva Goncalves Bos Nina Rol Christophe Guignabert Ly Tu Ingrid Schalij Karien C. Wiesmeijer Olga Tura-Ceide Anton Vonk Noordegraaf Frances S. de Man Harm Jan Bogaard Marie-José Goumans The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient Cells pulmonary arterial hypertension BMPR2 BMP and TGF-β signaling animal models of pulmonary hypertension |
| title | The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient |
| title_full | The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient |
| title_fullStr | The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient |
| title_full_unstemmed | The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient |
| title_short | The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient |
| title_sort | bmp receptor 2 in pulmonary arterial hypertension when and where the animal model matches the patient |
| topic | pulmonary arterial hypertension BMPR2 BMP and TGF-β signaling animal models of pulmonary hypertension |
| url | https://www.mdpi.com/2073-4409/9/6/1422 |
| work_keys_str_mv | AT chrishappe thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT kondababukurakula thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT xiaoqingsun thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT deniellidasilvagoncalvesbos thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT ninarol thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT christopheguignabert thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT lytu thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT ingridschalij thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT kariencwiesmeijer thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT olgaturaceide thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT antonvonknoordegraaf thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT francessdeman thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT harmjanbogaard thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT mariejosegoumans thebmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT chrishappe bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT kondababukurakula bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT xiaoqingsun bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT deniellidasilvagoncalvesbos bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT ninarol bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT christopheguignabert bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT lytu bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT ingridschalij bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT kariencwiesmeijer bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT olgaturaceide bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT antonvonknoordegraaf bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT francessdeman bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT harmjanbogaard bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient AT mariejosegoumans bmpreceptor2inpulmonaryarterialhypertensionwhenandwheretheanimalmodelmatchesthepatient |